"Bile Duct Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the BILE DUCTS.
| Descriptor ID |
D001650
|
| MeSH Number(s) |
C04.588.274.120.250 C06.130.120.120 C06.130.320.120 C06.301.120.250
|
| Concept/Terms |
Bile Duct Neoplasms- Bile Duct Neoplasms
- Bile Duct Neoplasm
- Neoplasm, Bile Duct
- Neoplasms, Bile Duct
Bile Duct Cancer- Bile Duct Cancer
- Bile Duct Cancers
- Cancer, Bile Duct
- Cancers, Bile Duct
- Cancer of the Bile Duct
- Cancer of Bile Duct
|
Below are MeSH descriptors whose meaning is more general than "Bile Duct Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Bile Duct Neoplasms".
This graph shows the total number of publications written about "Bile Duct Neoplasms" by people in this website by year, and whether "Bile Duct Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 4 | 0 | 4 |
| 2006 | 5 | 0 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 2 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
| 2022 | 6 | 0 | 6 |
| 2023 | 4 | 1 | 5 |
| 2024 | 3 | 1 | 4 |
| 2025 | 5 | 0 | 5 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bile Duct Neoplasms" by people in Profiles.
-
Intrahepatic cholangiocarcinoma treated with glass yttrium-90 radioembolization: A histopathologic study. Eur J Nucl Med Mol Imaging. 2026 Oct; 53(12):6920-6929.
-
Clinical Validation of AI-Assisted Evaluation of Indeterminate Biliary Strictures in Digital-Single Operator Cholangioscopy: A Transcontinental Multicentric Study. Clin Transl Gastroenterol. 2026 Jun 01; 17(6):e01015.
-
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma. Ann Surg Oncol. 2025 Oct; 32(10):7228-7239.
-
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis. Ann Surg Oncol. 2025 Oct; 32(10):7215-7227.
-
Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma. Hepatology. 2026 May 01; 83(5):1128-1142.
-
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel. Hepatol Commun. 2025 07 01; 9(7).
-
Minimum Requirements to Safely Establish and Sustain New Hepatic Arterial Infusion Pump Programs: An International Expert Perspective. Ann Surg Oncol. 2025 Jun; 32(6):4408-4416.
-
Survival Outcomes of Radiofrequency Ablation for Intrahepatic Cholangiocarcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database: Comparison with Radiotherapy and Resection. J Vasc Interv Radiol. 2025 03; 36(3):489-498.e3.
-
Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma. Am J Clin Oncol. 2024 08 01; 47(8):373-382.
-
Identification of RNF213 as a Potential Suppressor of Local Invasion in Intrahepatic Cholangiocarcinoma. Lab Invest. 2024 07; 104(7):102074.